✦ LIBER ✦

P.5.a.006 Long-term safety and tolerability of memantine: an open-label extension study in patients with mild to moderate Alzheimer's disease

✍ Scribed by S. Bakchine; M. Rainer

Book ID: 118594246
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 55 KB
Volume: 17
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(07)70818-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Open label, multicenter, 28-week extensi

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

✍ Brian R. Ott; Lesley M. Blake; Ethel Kagan; Malca Resnick; for the Memantine MEM 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 142 KB

Long-term safety and tolerability of rot

Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: A prospective, open-label extension study

✍ Lawrence W. Elmer; Erwin Surmann; Babak Boroojerdi; Joseph Jankovic 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 408 KB

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Safety and tolerability of rivastigmine

Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)

✍ Jason T. Olin; Vinod Bhatnagar; Patricio Reyes; Barbara Koumaras; Xiangyi Meng; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

## Abstract ## Objective Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild‐to‐moderate Alzheimer's disease (AD) and Parkinson's disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects an

Solanezumab was safe and well-tolerated

Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study

✍ Taro Goto; Shinji Fujikoshi; Kazunori Uenaka; Shinichi Nishiuma; Eric R. Siemers 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

A 26-week, Open-label Extension Study Ev

A 26-week, Open-label Extension Study Evaluating The Long-term Safety And Tolerability Of Ciclesonide Hydrofluoroalkane Nasal Aerosol In Patients With Perennial Allergic Rhinitis

✍ Storms, W.; Gross, G.; Spector, S.; Huang, H.; Desai, S.Y. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 39 KB